ProShare Advisors LLC Grows Stock Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

ProShare Advisors LLC grew its holdings in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 25.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 47,808 shares of the company’s stock after purchasing an additional 9,679 shares during the period. ProShare Advisors LLC’s holdings in Sana Biotechnology were worth $78,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its holdings in Sana Biotechnology by 229.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company’s stock worth $25,000 after acquiring an additional 10,548 shares during the last quarter. Cerity Partners LLC purchased a new position in Sana Biotechnology in the 4th quarter worth approximately $25,000. Syon Capital LLC purchased a new position in Sana Biotechnology in the 4th quarter worth approximately $27,000. Ameriprise Financial Inc. purchased a new position in Sana Biotechnology in the 4th quarter worth approximately $29,000. Finally, Blue Trust Inc. raised its holdings in Sana Biotechnology by 51.0% in the 4th quarter. Blue Trust Inc. now owns 19,823 shares of the company’s stock worth $32,000 after acquiring an additional 6,694 shares during the last quarter. 88.23% of the stock is currently owned by hedge funds and other institutional investors.

Sana Biotechnology Price Performance

Sana Biotechnology stock opened at $2.34 on Wednesday. Sana Biotechnology, Inc. has a 1-year low of $1.26 and a 1-year high of $7.91. The firm has a market capitalization of $527.62 million, a P/E ratio of -1.67 and a beta of 1.75. The company’s 50-day moving average is $1.78 and its 200 day moving average is $2.33.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. Research analysts anticipate that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on SANA shares. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Sana Biotechnology in a report on Thursday, April 24th. Jefferies Financial Group initiated coverage on Sana Biotechnology in a research report on Friday, March 14th. They issued a “buy” rating and a $7.00 target price on the stock. Finally, Citizens Jmp raised shares of Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a research report on Tuesday, March 18th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Sana Biotechnology presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.80.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.